Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16

por Yasui, H., Okita, Y., Nakamura, M., Sagawa, T., Watanabe, T., Kataoka, K., Manaka, D., Shiraishi, K., Akazawa, N., Okuno, T., Shimura, T., Shiozawa, M., Sunakawa, Y., Ota, H., Kotaka, M., Okuyama, H., Takeuchi, M., Ichikawa, W., Fujii, M., Tsuji, A.
Publicado 2023

Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7

por Takahashi, T., Yamazaki, K., Oki, E., Shiozawa, M., Mitsugi, K., Makiyama, A., Nakamura, M., Ojima, H., Kagawa, Y., Matsuhashi, N., Okuda, H., Asayama, M., Yuasa, Y., Shimada, Y., Manaka, D., Watanabe, J., Oba, K., Yoshino, T., Yoshida, K., Maehara, Y.
Publicado 2021